In DLBCL, the Deauville scoring system (DS) is the standard for PET/CT response assessment. An alternative system, based on the semi-quantitative change in standardized uptake values, namely ΔSUVmax, has been reported to be more objective than the DS. We aimed to compare ΔSUVmax and DS for risk stratification of DLBCL patients on end-of-treatment (EoT) PET. 108 consecutive patients were included. 2-year EFS Kaplan-Meier survival analyses and Cox regression models were performed. 2-year EFS was significantly different between favorable ΔSUVmax (favΔ < -86.5%) and unfavorable ΔSUVmax (unfavΔ ≥ -86.5%) patients: 100.0% ± 0.0 versus 58.3% ± 14.2 ( = 0.001). On Cox multivariable regression, ΔSUVmax status was the only independent predictor of 2-year EFS, outperforming DS. Therefore, ΔSUVmax should be computed for non-responder patients, especially DS4, as the 2-year EFS is not different between responders and non-responders in the case of favΔ. Further studies are needed in order to confirm this hypothesis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10428194.2021.1948028 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Outcomes of Hematopoietic Cell Transplantation in Children with Inborn Errors of Immunity: A Single-Center Series.
J Clin Immunol
December 2024
Department of Pediatrics, Division of Pediatric Hematology Oncology and Bone Marrow Transplantation, King Hussein Cancer Center, 202 Queen Rania Street, Amman, 11941, Jordan.
Inborn errors of immunity (IEI) are a heterogenous group of rare monogenic disorders that affect innate or adaptive immunity, resulting in susceptibility to life-threatening infections and autoimmunity. Allogeneic hematopoietic cell transplantation (HCT) is a valuable curative option for children with IEI. We conducted a retrospective single-center study on the outcome of HCT in children with IEI.
View Article and Find Full Text PDFA phase 2 pilot study of umbilical cord blood infusion as an adjuvant consolidation therapy in elderly patients with acute myeloid leukemia.
Signal Transduct Target Ther
December 2024
Shanghai Institute of Hematology, State Key Laboratory for Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Acute myeloid leukemia (AML) is an aging-related malignancy, with patients aged ≥60 years old facing significantly poorer prognosis. Umbilical cord blood (UCB) has emerged as a promising source with effective anti-aging roles. Here, we conducted a prospective, phase 2, single-arm trial of UCB infusion as an adjuvant consolidation therapy in elderly AML patients (ChiCTR-OPC-15006492).
View Article and Find Full Text PDFNeoadjuvant immunology therapy in patients with non-small cell lung cancer and chronic obstructive pulmonary disease.
J Thorac Dis
November 2024
Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Background: For patients with early non-small cell lung cancer (NSCLC) complicated with chronic obstructive pulmonary disease (COPD), the efficacy and safety of immunotherapy are still unclear. This study was designed to investigate the effect and safety of neoadjuvant immunotherapy for patients with resectable NSCLC including those with coexisting COPD and the effect on patients' lung function.
Methods: Data of patients with resectable NSCLC who received neoadjuvant immunotherapy at the Shanghai Chest Hospital were retrospectively analyzed.
Evaluating the safety and efficacy of proton radiotherapy for intracranial pediatric ependymomas: A single-arm meta-analysis.
J Clin Neurosci
December 2024
Department of Neurosurgery, State University of Campinas, Campinas, SP, Brazil.
Article Synopsis
- Ependymomas are a type of brain tumor in children, making up 6-10% of such cases, and this study looks at the effectiveness of proton therapy for treatment.
- A systematic review and meta-analysis were conducted, involving 908 patients from ten studies, focusing on survival rates and complications from the treatment.
- The results indicate that while proton radiotherapy shows promising safety and efficacy with high overall survival rates, caution is advised due to variability in some adverse event outcomes indicated by wide confidence intervals.
Response to induction chemotherapy as a prognostic indicator in locally advanced head and neck squamous cell carcinoma.
J Cancer Res Clin Oncol
December 2024
Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Article Synopsis
- Induction chemotherapy (IC) may be a viable treatment for locally advanced head and neck squamous cell carcinomas (HNSCC), and this study investigates its impact on patient survival outcomes.
- The study involved analyzing data from 48 patients at a cancer center, revealing that a significant portion responded positively to IC, with a 97% tumor control rate and a notable tumor reduction in many cases.
- The findings indicate that the response to IC is a strong predictor of survival, especially for patients with laryngeal and hypopharyngeal tumors, highlighting the efficacy of IC in this patient population.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!